echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Haichuang Pharmaceuticals Phase 2/3 Clinical Trial of AR Inhibitor Approved in Brazil

    Haichuang Pharmaceuticals Phase 2/3 Clinical Trial of AR Inhibitor Approved in Brazil

    • Last Update: 2021-07-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On July 12, Haichuang Pharmaceutical announced that its "HC-1119 New Coronary Inpatient Treatment Phase 2/3 Clinical Trial" application has been approved by the Brazilian Health Supervision Agency (ANVISA), and relevant clinical trials will be officially launched in Brazil
    .


    It is reported that the trial is a placebo-controlled, based on standard treatment, to evaluate the efficacy and safety of HC-1119 in the treatment of hospitalized patients with new coronary disease


    HC-1119 is an androgen receptor (AR) inhibitor.
    It is one of the core products under development of Haichuang Pharmaceutical.
    It is simultaneously carrying out a global multi-center clinical phase 3 trial for the treatment of prostate cancer and a clinical phase 3 trial in China
    .



    If this article violates your rights, please contact us


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.